IL-23 Inhibitors for Active Crohn's Disease
Part of Digestive system clinical trials.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Confirmed Crohn's disease diagnosis with active inflammation shown by endoscopy, imaging, or blood/stool tests
- Planning to start an IL-23 inhibitor (guselkumab or risankizumab) as your next treatment
- Never previously taken an IL-23 inhibitor
- No active infection, tuberculosis, or hepatitis B/C
- Not pregnant, not breastfeeding, and willing to use contraception during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
This study is gathering information on how well Il-23 inhibitors work and how safe they are for people with ulcerative colitis or Crohn's disease in China. It is a real-world study, meaning it looks at people using these drugs in everyday medical practice.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.